Category: Medications
-
Americans’ Ability to Afford Health Care Falls to a 5‑Year Low
For the first time in half a decade, fewer than half of American adults say they can consistently afford the health care they need. This shift is not a small dip or a one‑year anomaly. It reflects a steady decline in affordability that has been building since 2021, and the newest data shows the problem…
-
Truqap Becomes the First Targeted Therapy for PTEN‑Deficient Metastatic Prostate Cancer
Prostate cancer remains one of the most common cancers affecting men worldwide, and while many cases respond well to early treatment, advanced forms of the disease can be far more difficult to manage. A major challenge has been finding effective therapies for aggressive subtypes that grow and spread quickly. One of these subtypes involves tumors…
-
FDA Approves Cavhanza for Philadelphia Chromosome Positive Chronic Myeloid Leukemia
When the FDA approves a new cancer treatment, it often signals a meaningful step forward for patients who need more flexible or effective options. That is exactly what happened with Cavhanza, a newly approved orally disintegrating tablet (ODT) formulation of nilotinib for adults with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). Cavhanza is designed…
-
FDA Approves Decnupaz, the First Antibody-Drug Conjugate for Blastic Plasmacytoid Dendritic Cell Neoplasm
The U.S. Food and Drug Administration has approved Decnupaz (pivekimab sunirine-pvzy), marking a major step forward for people facing blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This is an extremely rare and aggressive blood cancer that has historically offered patients very few effective treatment options. With this approval, adults diagnosed with BPDCN – whether newly…
-
Datroway Receives FDA Approval for Advanced Triple‑Negative Breast Cancer: What This Breakthrough Means for Patients
Triple‑negative breast cancer, often shortened to TNBC, has long been one of the most challenging forms of breast cancer to treat. Unlike other breast cancer types, TNBC does not have the three common receptors that many modern treatments target. This means patients have historically had fewer options, and many have had to rely on chemotherapy…
-
FDA Approves Fasenra as an Under the Skin Shot to Help Reduce Flares in Hypereosinophilic Syndrome
When the FDA approves a new treatment for a rare and difficult condition, it often marks a turning point for patients who have spent years dealing with unpredictable symptoms. That is exactly what happened with the approval of Fasenra, a medication given as an under the skin shot that has now been cleared to help…
-
The Lyme Disease Vaccine guide: What to Know, What’s Coming, and What It Means for You
Lyme disease has become a growing concern across much of the United States, especially in the Northeast, Midwest, and parts of the West Coast. Each year, hundreds of thousands of people are diagnosed or treated for Lyme disease, a bacterial infection spread by blacklegged ticks. For decades, prevention has relied almost entirely on avoiding tick…
-
Icotyde – a new psoriasis treatment pill
The U.S. Food and Drug Administration has approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in adolescents 12 years and older who weigh at least 40 kg. This is notable because Icotyde is an oral, once-daily medication that targets the IL‑23 receptor, a key part of the immune pathway that…
-
BIMZELX vs SKYRIZI – one stands out in a head‑to‑head trial
A new head‑to‑head study found that bimekizumab (brand name BIMZELX) produced better short‑term joint improvement than risankizumab (brand name SKYRIZI) in adults with active psoriatic arthritis (PsA). The trial’s primary measure was ACR50 – a commonly used, fairly strict standard that means a patient has achieved at least a 50% improvement in joint signs and…
-
FDA approves first generic of Flovent HFA: what this means for people with asthma
If you or a family member uses Flovent HFA or another inhaled steroid to control asthma, this week’s news could affect how easily you get that medicine and how much it costs. The U.S. Food and Drug Administration has approved the first true generic version of Flovent HFA (fluticasone propionate) inhalation aerosol, 44 micrograms per…